A few weeks ago on the pharmaphorum podcast, we discussed the new GLP-1 weight loss drugs and their shake-up effect on the medical weight loss industry.
Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.